Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs.
A method for determination of the atypical neuroleptic drug olanzapine in serum was developed. After a single-step liquid-liquid extraction, the compound was separated from other constituents on a normal-phase silica gel column using a buffer-methanol mobile phase and measured by UV absorption at 270 nm. Addition of 0.25% ascorbic acid to serum protects olanzapine against oxidation during extraction and stabilizes the easily oxidised compound during storage. Inter-day variation was <8% at serum levels found in olanzapine treated patients. Analytical interference from coadministered psychoactive drugs and their metabolites were studied. Only risperidone, also a relatively newly developed antipsychotic drug, interfered, but the most commonly used antidepressants and traditional antipsychotics and their metabolites did not interfere.
Institute for Basic Research in Psychiatry, Department of Biological Psychiatry, Psychiatric Hospital, Risskov, Denmark.
O V
OV
Olesen
K
K
Linnet
D014150:Antipsychotic Agents / Q000097:blood* / Q000737:chemistry; D016477:Artifacts; D001205:Ascorbic Acid / Q000737:chemistry; D001569:Benzodiazepines; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D000077152:Olanzapine; D010084:Oxidation-Reduction; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000097:blood / Q000737:chemistry; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine; D001205:Ascorbic Acid